These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 198380)

  • 1. Epstein-Barr herpesvirus infection: inhibition by immunologically induced mediators with interferon-like properties.
    Lai PK; Alpers MP; MacKay-Scollay EM
    Int J Cancer; 1977 Jul; 20(1):21-9. PubMed ID: 198380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of cell-mediated immunity to Epstein-Barr herpesvirus by cell migration inhibition tests.
    Lai PK; Alpers MP; Mackay Scollay EM
    J Natl Cancer Inst; 1975 Dec; 55(6):1319-22. PubMed ID: 173867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of an Epstein-Barr virus-associated membrane antigen in Epstein-Barr virus-transformed nonproducer cells by leukocyte migration inhibition and blocking antibody.
    Szigeti R; Sulitzeanu D; Henle G; Henle W; Klein G
    Proc Natl Acad Sci U S A; 1984 Jul; 81(13):4178-82. PubMed ID: 6330746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell mediated immunity during infectious mononucleosis to Epstein-Barr virus associated antigens.
    Periman P; Levine PH; Ablashi DV; Royston I
    Int J Cancer; 1977 Oct; 20(4):506-11. PubMed ID: 199544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Release of lymphokines after Epstein Barr virus infection in vitro. I. Sources of and kinetics of production of interferons and interleukins in normal humans.
    Lotz M; Tsoukas CD; Fong S; Dinarello CA; Carson DA; Vaughan JH
    J Immunol; 1986 May; 136(10):3636-42. PubMed ID: 3009608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukocyte migration inhibition detects cross-reacting antigens between cells transformed by Epstein-Barr virus (EBV) and EBV-like simian viruses.
    Szigeti R; Rabin H; Timar L; Klein G
    Intervirology; 1986; 26(3):121-8. PubMed ID: 3034820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-mediated immunity to Epstein-Barr virus and a blocking factor in patients with infectious mononucleosis.
    Lai PK; Mackay-Scollay EM; Fimmel PJ; Alpers MP; Keast D
    Nature; 1974 Dec; 252(5484):608-10. PubMed ID: 4372559
    [No Abstract]   [Full Text] [Related]  

  • 8. Cell-mediated immunity, Epstein-Barr virus and nasopharyngeal carcinoma.
    Levine PH; Lamelin JP; Stevens DA
    IARC Sci Publ (1971); 1978; (20):483-94. PubMed ID: 215530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukocyte migration inhibition demonstrates a human T-cell response to a membrane protein expressed in latent Epstein-Barr virus infection.
    Sulitzeanu D; Szigeti R; Klein G; Hennessy K; Kieff E
    J Virol; 1986 Apr; 58(1):230-2. PubMed ID: 3005653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic properties of Epstein-Barr virus-seronegative adults.
    Jabs WJ; Wagner HJ; Neustock P; Klüter H; Kirchner H
    J Infect Dis; 1996 May; 173(5):1248-51. PubMed ID: 8627079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the defects responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation.
    Hasler F; Bluestein HG; Zvaifler NJ; Epstein LB
    J Exp Med; 1983 Jan; 157(1):173-88. PubMed ID: 6294213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization.
    Yao QY; Rowe M; Morgan AJ; Sam CK; Prasad U; Dang H; Zeng Y; Rickinson AB
    Int J Cancer; 1991 Apr; 48(1):45-50. PubMed ID: 1850382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum modulation of in vitro cellular immune reactivity to Epstein-Barr virus-associated antigen.
    Holt PG; Fimmel PJ; Roberts LM; Keast D
    Med Microbiol Immunol; 1976 Dec; 162(3-4):209-16. PubMed ID: 187919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Migration inhibition caused by EBV-specific 48K subcomponent of EBNA and the associated 53K cellular protein.
    Szigeti R; Luka J; Sternås L; Klein G
    Int J Cancer; 1982 Apr; 29(4):413-6. PubMed ID: 6282766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of leucocyte inhibitory factor (LIF) and macrophage inhibitory factor (MIF) by PHA-stimulated lymphocytes.
    Ruthlomnitzer ; Rabson AR; Koornhof HJ
    Clin Exp Immunol; 1975 Dec; 22(3):522-7. PubMed ID: 773578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus-specific leukocyte migration inhibition reaction with tumor biopsy extracts: correlation with the presence of viral DNA.
    Szigeti R; Saemundsen AK; Synnerholm AC; Henle G; Henle W; Klein G
    Cancer Res; 1983 May; 43(5):2273-6. PubMed ID: 6299543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The agarose migration inhibition technique for in vitro demonstration of cell-mediated immunity in man. A review.
    Clausen JE
    Dan Med Bull; 1975 Jul; 22(5):181-94. PubMed ID: 126141
    [No Abstract]   [Full Text] [Related]  

  • 18. Epstein-Barr virus susceptibility of normal human B lymphocyte populations.
    Aman P; Ehlin-Henriksson B; Klein G
    J Exp Med; 1984 Jan; 159(1):208-20. PubMed ID: 6319530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-interleukin-10 antibodies in patients with chronic active Epstein-Barr virus infection.
    Tanner JE; Diaz-Mitoma F; Rooney CM; Alfieri C
    J Infect Dis; 1997 Dec; 176(6):1454-61. PubMed ID: 9395354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus infections.
    Middleton PJ
    Can Med Assoc J; 1974 Jan; 110(1):9-10. PubMed ID: 4358535
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.